Oocyte (Egg) Donation — Cost, Top Hospitals & Success Rates | MyMedicPlus

Oocyte (egg) donation is an assisted reproductive technology (ART) in which mature eggs (oocytes) retrieved from a fertile woman (the donor) are fertilised with sperm — from the recipient's partner or a sperm donor — and the resulting embryo(s) transferred into the uterus of the recipient (the intended mother or gestational carrier). It is one of the most effective fertility treatments available, bypassing the biological barriers of ovarian age, ovarian failure, and poor oocyte quality that limit success with a woman's own eggs.

The key principle enabling egg donation is the separation of ovarian function (egg production — donor dependent) from uterine function (implantation and gestation — recipient dependent). The uterus maintains its ability to support pregnancy well into the mid-50s in most women, even when the ovaries have failed completely. Exogenous oestrogen and progesterone supplementation prepares the recipient's endometrium (uterine lining) independently of any requirement for ovarian hormones.

Egg donation may use fresh or frozen (vitrified) oocytes. Since the introduction of vitrification — ultra-rapid cryopreservation that avoids damaging ice crystal formation — frozen egg donation has become the predominant model in most countries. Vitrified eggs survive the freeze-thaw process at rates of 80–95%, with equivalent fertilisation and live birth rates to fresh eggs in randomised trials. Frozen donation enables donor recruitment and testing, genetic carrier screening, and flexible scheduling without the need to synchronise donor and recipient menstrual cycles.

Egg donation accounts for approximately 10–15% of all IVF cycles in Europe and the US, with substantially higher proportions in countries with older average maternal age at first conception. Spain, the Czech Republic, and Greece are major medical tourism destinations for egg donation, offering high-quality regulated care at lower cost than the UK, US, or Australia.

Egg donation is indicated when a woman cannot produce viable eggs of her own, or when her eggs carry an unacceptable risk of transmitting a serious genetic disorder.

• Premature Ovarian Insufficiency (POI, formerly Premature Ovarian Failure): Ovarian failure before age 40, characterised by FSH >25 IU/L and oestradiol <30 pg/mL on two occasions at least 4 weeks apart. Causes include: autoimmune (most common in adults — associated with thyroid disease, Addison's disease), iatrogenic (chemotherapy with alkylating agents; ovarian radiation), chromosomal (Turner syndrome 45,X, mosaic Turner; Fragile X premutation FMR1 CGG repeat expansion — a major genetic cause of POI), and idiopathic (40% of cases). These women have essentially no viable own-oocyte pool and require donor eggs to achieve pregnancy.
• Advanced Reproductive Age (>43 years): Oocyte aneuploidy rates rise dramatically with maternal age — exceeding 80% at age 43 and approaching 90–95% at age 46. Even with preimplantation genetic testing (PGT-A), the number of viable euploid embryos per stimulation cycle falls to near zero in most women over 44. Egg donation bypasses age-related chromosomal abnormality, achieving live birth rates equivalent to the donor's age (typically 18–34 years).
• Diminished Ovarian Reserve (DOR) in Younger Women: Poor ovarian response to stimulation (antral follicle count <5 bilaterally, AMH <0.5–1.0 ng/mL, FSH >10–15 IU/L) leading to cancelled cycles or very few eggs retrieved even after maximal stimulation doses. After documented failure of protocols including high-dose FSH, growth hormone adjuncts, or DHEA supplementation, egg donation may be recommended.
• Repeated IVF Failure with Own Eggs: Three or more failed IVF cycles with good-quality embryos (without identifiable uterine or implantation factor) suggests poor oocyte quality; switching to donor eggs often achieves success in subsequent cycles.
• Genetic Indications: Carriers of serious X-linked conditions (haemophilia A, Duchenne muscular dystrophy, Fragile X syndrome), high-penetrance autosomal dominant conditions (BRCA1/2 with personal wish to avoid transmission), or homozygous or compound-heterozygous carriers where preimplantation genetic testing (PGT-M) with own eggs is not feasible or has failed.
• Surgical Oophorectomy: Bilateral removal of ovaries for malignancy risk reduction (BRCA carriers), severe endometriosis, or ovarian malignancy — where fertility preservation was not possible before surgery.

Both donors and recipients undergo comprehensive medical, genetic, psychological, and legal assessment before commencing an egg donation cycle.

Recipient Eligibility:

• Age: Most clinics accept recipients up to age 50–54; some extend to 55 years or beyond with institutional ethics committee approval. The uterus remains functional with adequate hormonal support; the primary limitation is the recipient's medical fitness for pregnancy rather than uterine age. Pregnancy at advanced maternal age carries elevated risks of gestational hypertension, pre-eclampsia, gestational diabetes, caesarean section, and maternal cardiovascular complications.
• Uterine assessment: Hysteroscopy to exclude endometrial polyps, submucosal fibroids, and intrauterine adhesions (Asherman's syndrome). MRI of the pelvis if anatomical anomalies suspected on scan. Uterine cavity must be normal or correctable to proceed.
• Cervical smear up to date (3–5 year guidelines depending on country).
• Medical fitness: For recipients over 45, comprehensive cardiovascular evaluation including ECG and echocardiogram; endocrinology review if T2DM, thyroid disease, or hypertension present; haematology input for thrombophilia screening. Pre-existing conditions must be optimised before embryo transfer.
• Psychological assessment: Mandatory in most regulatory frameworks; dedicated counselling session with an accredited fertility counsellor to explore motivations, explore feelings about genetic asymmetry between partners (recipient not genetically related to child), discuss disclosure to the child, and assess psychological readiness and support systems.

Donor Eligibility:

• Age 18–34 years (ASRM/ESHRE guidance; HFEA in UK: 18–35)
• BMI <30 kg/m² (most protocols; some centres accept up to 32)
• Normal ovarian reserve: antral follicle count (AFC) ≥8 bilaterally, AMH ≥1.0 ng/mL
• Normal karyotype (46,XX); expanded genetic carrier screening (200–300+ conditions, including cystic fibrosis, SMA, Fragile X carrier status, haemoglobinopathies, and others depending on ethnic background)
• Infectious disease panel per HFEA/FDA guidelines: HIV-1/2, hepatitis B (HBsAg, anti-HBc), hepatitis C, syphilis, HTLV-I/II, CMV, Chlamydia, gonorrhoea
• Psychological assessment and independent counselling — particularly important for known (emotionally related) donors
• No personal or immediate family history of inheritable conditions affecting quality of life or life expectancy

An egg donation cycle involves parallel or sequential steps for donor and recipient, co-ordinated by the clinical embryology team:

Step 1 — Donor Ovarian Stimulation: The donor undergoes controlled ovarian hyperstimulation (COH) using subcutaneous FSH or FSH/LH combination gonadotropins (typically 150–300 IU/day, adjusted according to follicular response on serial transvaginal ultrasound). A GnRH antagonist protocol (cetrorelix or ganirelix, commenced when leading follicle reaches 12–14 mm) or long GnRH agonist protocol suppresses premature luteinisation. When ≥3 follicles reach ≥17 mm diameter, ovulation is triggered.

Trigger Shot: For fresh donation cycles: hCG trigger (5,000–10,000 IU) 34–36 hours before retrieval. For donors at risk of OHSS or in all frozen donation cycles: GnRH agonist trigger (leuprolide acetate 0.5–1 mg or buserelin 0.5 mg) — this dramatically reduces the risk of severe ovarian hyperstimulation syndrome (OHSS) in the donor by avoiding the prolonged LH receptor stimulation of hCG.

Step 2 — Oocyte Retrieval: Performed under intravenous sedation (propofol-based) with transvaginal ultrasound guidance. A needle is passed through the vaginal wall into each follicle; follicular fluid containing the oocyte is aspirated and immediately examined by the embryologist. A typical retrieval yields 10–20 mature (MII) oocytes in a young donor with normal ovarian reserve.

Step 3 — Fertilisation by ICSI: Intracytoplasmic sperm injection (ICSI) is used for all donor egg cycles — a single selected sperm is injected directly into each mature egg. This ensures maximum fertilisation rates (75–85% of MII oocytes fertilised) regardless of sperm quality, and avoids the theoretically suboptimal fertilisation conditions of conventional IVF with donor eggs.

Step 4 — Embryo Culture to Blastocyst: Fertilised eggs (zygotes) are cultured in time-lapse incubators for 5–6 days. Blastocysts are graded using the Gardner system (expansion + inner cell mass + trophectoderm grades, e.g., 4AA, 3BB). Only blastocysts graded ≥3BB or above are suitable for transfer or cryopreservation. Preimplantation Genetic Testing for Aneuploidy (PGT-A) using trophectoderm biopsy and next-generation sequencing (NGS) is offered to identify chromosomally normal (euploid) embryos — improving implantation rates to 60–70% per euploid blastocyst transferred.

Step 5 — Recipient Endometrial Preparation:

• Artificial (hormone replacement) cycle: Exogenous oestradiol (oral, transdermal, or vaginal — commenced cycle day 1–3) builds the endometrium to ≥7–8 mm trilaminar appearance (monitored by transvaginal ultrasound, typically by day 10–14). Progesterone (micronised vaginal progesterone 400 mg twice daily or 600 mg/day, or intramuscular progesterone in oil 50 mg/day) is commenced 5 days before planned blastocyst transfer (P+5 protocol). This approach does not depend on the recipient's endogenous ovarian function — ideal for POI and postmenopausal recipients. The timing is fully programmable.
• Natural cycle / Modified natural cycle: For ovulatory recipients, the natural LH surge (or hCG trigger) and endogenous progesterone support blastocyst transfer. Lower medication burden; reserved for recipients with regular cycles and frozen embryo transfers only.

Step 6 — Embryo Transfer: Single euploid blastocyst transfer (SET) is the standard of care, reducing multiple pregnancy rate to <3% while maintaining per-transfer live birth rates of 55–65%. Two-embryo transfer may be considered for repeated implantation failure or recipients over 45. Transfer is an outpatient ultrasound-guided procedure.

Step 7 — Luteal Phase Support: Oestradiol and progesterone continued until beta-hCG at 12–14 days; if positive, luteal support continues to 10–12 weeks of gestation when placental progesterone production is sufficient.

Egg donation IVF achieves the highest live birth rates of any ART procedure, and provides unique benefits for specific patient populations that no other fertility treatment can replicate.

Success Rates:

• Live birth rate per transfer (single euploid blastocyst, frozen donor egg IVF): 50–65% — the most effective single-cycle fertility treatment available
• Cumulative live birth rate from a single donation batch (all resulting embryos transferred sequentially): 70–85% at major donor egg programmes
• Comparison: own-egg IVF live birth rates at age 40 = 15–20% per cycle; at age 43 = 5–10%; at age 45 = 1–5%. Donor egg IVF bypasses this age curve entirely.
• With PGT-A selection: implantation rate per euploid blastocyst reaches 65–70% in experienced embryology laboratories

Bypassing Age-Related Oocyte Aneuploidy: The primary benefit for older recipients. Because the oocyte is from a young donor (18–34 years), chromosomal abnormality rates are equivalent to a young woman's eggs — approximately 20–30% aneuploidy at age 25, versus 80–90% in a woman's own eggs at age 44. This eliminates the most common cause of IVF failure and miscarriage in older women.

Benefits for Premature Ovarian Insufficiency: For women with POI — who have essentially no viable own eggs — donor egg IVF is the only fertility treatment that can achieve pregnancy. Live birth rates are equivalent to other donor egg recipients of similar age, as uterine function in POI is typically preserved. Long-term oestrogen replacement for POI also maintains endometrial receptivity.

Gestational and Genetic Parenthood: The recipient carries the pregnancy, giving birth to the child. While the child is not genetically related to the birth mother, she is the gestational mother — contributing the intrauterine environment, nutrient provision, epigenetic programming, and maternal microbiome transfer. Growing evidence in epigenetics demonstrates that maternal factors including uterine microenvironment, nutrition, stress hormones, and immune signals substantially influence fetal gene expression during pregnancy.

Expanded Genetic Donor Screening: Donors undergo comprehensive expanded carrier screening (200–300+ conditions), karyotype, and infectious disease panel — providing recipient couples with significantly more genetic information about the donor than is available in natural conception.

Reduced Multiple Pregnancy Risk: The near-universal adoption of single embryo transfer (SET) policy for donor egg IVF reduces twin pregnancy rates to <3%, eliminating the majority of ART-related adverse neonatal outcomes.

Egg donation IVF involves separate risk profiles for the donor (who undergoes ovarian stimulation and egg retrieval) and the recipient (who undergoes endometrial preparation and carries the pregnancy).

Risks to the Donor:

• Ovarian Hyperstimulation Syndrome (OHSS): The most significant donor risk. Moderate OHSS (abdominal bloating, nausea, fluid accumulation) occurs in 1–3% of stimulation cycles; severe OHSS (requiring hospitalisation, pleural effusion, haemoconcentration, VTE risk) in <0.1–1% when GnRH agonist trigger is used. The shift from hCG to GnRH agonist trigger in donor cycles has dramatically reduced severe OHSS incidence.
• Oocyte retrieval complications: Vaginal bleeding at puncture site (<1% requiring intervention); pelvic infection/oophoritis (<0.1%); rare bowel or vascular injury (<0.01%); anaesthetic complications from IV sedation
• Long-term ovarian cancer risk: Large registry studies (Brinton et al., Cancer Epidemiology 2013; Jensen et al., 2015) have not demonstrated a statistically significant increase in ovarian cancer risk from fertility drugs used for IVF stimulation at 5–10 year follow-up; no long-term donor-specific outcome data extending beyond 10 years yet published. HFEA and ASRM consider the procedure safe for appropriately screened donors.
• Psychological: Some donors report emotional complexity regarding genetic offspring they will never meet; counselling before and after donation is important; identity-release regulations in the UK mean donor-conceived individuals may contact biological donors at age 18

Risks to the Recipient and Pregnancy:

• Failed implantation: Despite optimal donor egg IVF, approximately 35–50% of single blastocyst transfers do not result in live birth. Causes include endometrial receptivity issues, embryo quality, and random chance.
• Pregnancy complications at advanced maternal age: Egg donation IVF in women over 45 carries elevated obstetric risks: pre-eclampsia (2–3× background risk), gestational diabetes, preterm labour, placenta praevia/accreta, and postpartum haemorrhage. The perinatal risk is similar to the recipient's own age, not the donor's age — reflecting the uterine and vascular age of the recipient. High-risk obstetric care and specialist multidisciplinary input are essential.
• Multiple pregnancy (if double embryo transfer): Twin pregnancy carries significantly elevated risk of preterm birth, low birth weight, and perinatal complications; SET policy mitigates this substantially
• Miscarriage: Approximately 15–20% of donor egg IVF pregnancies end in miscarriage — lower than age-matched own-egg IVF due to younger oocyte karyotype, but still approximately the background population rate for the embryo's chromosomal age

Post-transfer care focuses on luteal phase support, early pregnancy confirmation, and seamless transition to high-risk obstetric care for recipients at elevated risk.

Luteal Phase and Early Pregnancy (Days 1–84):

• Oestradiol and progesterone supplementation continues from embryo transfer until 10–12 weeks of gestation — the point at which placental steroidogenesis (luteoplacental shift) is established. Abrupt cessation before this point risks corpus luteum-deficient miscarriage in natural cycles, or hormonal withdrawal in artificial cycles.
• Serum beta-hCG at 12–14 days post-transfer: positive result (>5 mIU/mL) confirms biochemical pregnancy; the doubling time (every 48 hours) distinguishes a viable intrauterine pregnancy from biochemical failure or ectopic
• Transvaginal ultrasound at 6–7 weeks gestation to confirm intrauterine location and fetal cardiac activity
• Second scan at 8–10 weeks to confirm ongoing viability and crown-rump length before transition to obstetric care

Pregnancy Monitoring:

• Low-dose aspirin 75–150 mg/day from the time of embryo transfer or confirmed pregnancy until 36 weeks — significantly reduces pre-eclampsia risk (ASPRE trial data: 62% relative risk reduction when commenced before 16 weeks in high-risk women)
• Blood pressure monitoring: weekly self-monitoring from 20 weeks; in-clinic measurements at each antenatal visit; specialist referral if systolic >140 or diastolic >90 mmHg
• Gestational diabetes screening: 2-hour 75 g OGTT at 24–28 weeks gestation; HbA1c at first antenatal visit for women with risk factors
• Uterine artery Doppler at 20–24 weeks to assess placentation and pre-eclampsia risk

Psychosocial Follow-up:

• Disclosure counselling: HFEA, ESHRE, and ASRM guidelines support early age-appropriate disclosure of donor conception to children. Research consistently shows that donor-conceived individuals who learn of their origins in childhood (rather than discovering inadvertently in adulthood) report better psychological adjustment and family relationships.
• Genetic paternity testing services: DNA testing is now consumer-accessible; couples are counselled that genetic relatives of the donor may appear in commercial DNA databases, effectively making anonymous donation increasingly de facto identity-releasing even in countries with anonymous donation policies

Donor Follow-up:

• Post-retrieval review at 2 weeks for symptoms of OHSS or infection
• Recommended 3-month hormonal assessment (FSH, AMH, AFC) to confirm recovery of ovarian reserve
• Documentation of donation for medical records; regulatory reporting to HFEA (UK) or state registries where applicable

Egg donation IVF is significantly more expensive than standard IVF with own eggs due to the additional process of recruiting, screening, stimulating, and compensating a separate egg donor. Costs vary substantially by country, reflecting both regulatory frameworks (compensation rules) and healthcare economics.

Key Cost Components:

• Donor recruitment and compensation: In the US, donors may receive $5,000–$50,000 per cycle (total compensation, including time and inconvenience); in the UK, HFEA regulations permit compensation of up to £750 per donation cycle plus verifiable expenses; in Spain, Czech Republic, and Greece, compensation is set by national legislation at €800–€1,400; in Australia, only altruistic donation without payment is permitted
• Donor medical workup: Karyotype, expanded carrier screen ($800–$2,500), infectious disease panel, psychological assessment, AMH/AFC testing, and monitoring ultrasounds
• Donor stimulation medications: FSH gonadotropins ($2,000–$4,000 per stimulation cycle); GnRH antagonist protocol drugs
• Oocyte retrieval (donor): Anaesthesia, OR time, embryology laboratory time for oocyte identification and denudation
• ICSI, embryo culture to blastocyst: Embryology laboratory fees
• PGT-A (optional): Biopsy, vitrification, and NGS analysis adds $2,000–$5,000 per batch
• Frozen embryo transfer (recipient): Endometrial preparation medications (oestradiol + progesterone: $300–$800), ultrasound monitoring, and transfer procedure

Approximate Total Costs by Country (2025):

• United States (fresh or frozen donor egg bank cycle): $25,000–$50,000+ including donor compensation
• United Kingdom (licensed clinic, identity-release): £8,000–£15,000 (frozen egg bank); £12,000–£20,000 (fresh donor)
• Spain (licensed clinic): €5,000–€9,000 total cycle cost including anonymous donor
• Czech Republic / Greece: €4,000–€8,000 — the most cost-effective regulated destinations in Europe
• India (ICMR-regulated clinic): $4,000–$8,000

NHS/Public Funding: In the UK, NHS funding for egg donation IVF is extremely limited and varies by Clinical Commissioning Group (CCG); most recipients fund treatment privately. NICE guideline NG156 (2023) recommends offering funded IVF including with donor eggs to eligible women, but implementation varies widely. Most European national health systems do not fund donor egg IVF.

Medical Tourism Considerations: Spain, the Czech Republic, and Greece are the most popular egg donation destinations for UK, Northern European, and Australian patients, offering high-quality regulated care within the EU framework at 40–60% lower cost than UK private clinics. Key considerations: ensure the clinic is licensed by the national regulatory authority, all donor genetic testing is disclosed, and a fertility clinic in the home country manages early pregnancy follow-up.

Alternatives depend on the specific indication for egg donation. For some patients, other ART approaches may be appropriate; for others, egg donation represents the only pathway to pregnancy.

IVF with Own Eggs (with adjuncts for Poor Ovarian Response):

• Indicated for younger women (<40) with diminished ovarian reserve who have not yet undergone 3+ stimulation cycles. Adjuncts with some evidence include: DHEA supplementation (75 mg/day for 3 months — small RCTs show improved oocyte yield in DOR); CoQ10 (Coenzyme Q10, 400–800 mg/day — modest benefit in some studies); recombinant LH co-stimulation; growth hormone as adjunct (POSEIDON criteria guidance); intraovarian PRP (platelet-rich plasma) injection — experimental, limited evidence
• PGT-A with own eggs: reduces miscarriage risk and improves per-transfer success but does not overcome severely diminished oocyte yield; becomes unviable when <3 eggs retrieved per stimulation

Donor Embryo (Embryo Adoption):

• Both egg and sperm are from donors, generating embryos that are transferred to the recipient. Relevant when there is both female and male factor infertility, or when genetic testing of the sperm source is also desired. Fewer legal complexities in some jurisdictions; lower cost than dual-donor IVF. Surplus embryos donated by other IVF couples (known as embryo adoption or embryo donation) are available in some programmes.

Gestational Surrogacy (with Donor Eggs):

• When both ovarian failure and uterine factor are present (absent uterus, severe Asherman's syndrome, recurrent implantation failure), donor eggs can be used with a gestational surrogate who carries the pregnancy. Complex legal arrangements vary substantially by country; surrogacy is prohibited or severely restricted in many European countries.

Fertility Preservation Before Ovarian Failure:

• For women at high risk of POI (BRCA2 carriers, women about to undergo chemotherapy, Fragile X premutation carriers): egg or embryo freezing before treatment preserves own genetic material. Ovarian tissue cryopreservation and transplantation offers fertility restoration after cancer treatment with promising live birth rates (>40%) at specialist centres.

Adoption:

• A non-medical path to parenthood; increasingly slow processes in most Western countries due to fewer children available. Domestic adoption processes take 2–5+ years in the UK and US; international adoption has become significantly more restricted since The Hague Convention.

Remaining Childless / Child-free:

• A valid and personally significant decision for some couples facing complex fertility challenges. Psychological support and counselling to process involuntary childlessness is an important component of comprehensive fertility care. The British Infertility Counselling Association (BICA) and RESOLVE (US) provide specialist support.